Statins potentiate the anticoagulant effects of low molecular weight heparin

被引：0
|
作者：
Puppala, S [1 ]
Zimecki, K [1 ]
Zimmer, J [1 ]
Arora, RR [1 ]
Bhatt, B [1 ]
Houghton, J [1 ]
Chowdhury, M [1 ]
Spillert, CR [1 ]
机构：
[1] Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2003年 / 41卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：256A / 256A
页数：1
相关论文
共 50 条
  • [21] ANTICOAGULANT AND ANTIPLATELET ACTIVITIES OF HEPARIN AND LOW-MOLECULAR-WEIGHT DERIVATIVES
    CARR, ME
    PARK, A
    ZEKERT, SL
    MARQUES, D
    GOLDMAN, ID
    SOBEL, M
    BLOOD, 1993, 82 (10) : A603 - A603
  • [22] ANTICOAGULANT EFFECTS IN HUMAN VOLUNTEERS AFTER SUBCUTANEOUS ADMINISTRATION OF HEPARIN AND OF 2 TYPES OF LOW-MOLECULAR WEIGHT HEPARIN
    HOLMER, E
    BERGQVIST, D
    HEDNER, U
    THROMBOSIS AND HAEMOSTASIS, 1983, 50 (01) : 91 - 91
  • [23] Patient weight does not affect anticoagulant response to low molecular weight heparin (LMWH).
    Anderson, DR
    Wilson, JA
    Wilbur, K
    BLOOD, 1999, 94 (10) : 25A - 25A
  • [24] Very low doses of unfractionated heparin potentiate the anti-Xa activity of low molecular weight heparin (Enoxaparin)
    PerezRequejo, JL
    LucenaSolano, O
    PerezGarcia, M
    Santarelli, MT
    THROMBOSIS AND HAEMOSTASIS, 1997, : P1172 - P1172
  • [25] Very low doses of unfractionated heparin potentiate the anti-Xa activity of low molecular weight heparin (enoxaparin)
    PerezRequejo, JL
    LucenaSolano, O
    PerezGarcia, M
    Santarelli, MT
    THROMBOSIS RESEARCH, 1997, 85 (03) : 259 - 265
  • [26] Antiproliferative effects of low molecular weight heparin
    Fletcher, JP
    Ao, PY
    Hawthorne, WJ
    ANZ JOURNAL OF SURGERY, 2004, 74 (09) : 793 - 796
  • [27] Heparin and low-molecular-weight heparin therapy for venous thromboembolism - The twilight of anticoagulant monitoring
    Hull, RD
    Pineo, GF
    Stein, P
    INTERNATIONAL ANGIOLOGY, 1998, 17 (04) : 213 - 224
  • [28] Anticoagulant effects and tissue factor pathway inhibitor after intrapulmonary low-molecular-weight heparin
    Harenberg, J
    Malsch, R
    Angelescu, M
    Lange, C
    Michaelis, HC
    Wolf, H
    Heene, DL
    BLOOD COAGULATION & FIBRINOLYSIS, 1996, 7 (04) : 477 - 483
  • [29] Effects of intensive insulin therapy combined with low molecular weight heparin anticoagulant therapy on severe pancreatitis
    Du, Jun-Dong
    Zheng, Xi
    Huang, Zhi-Qiang
    Cai, Shou-Wang
    Tan, Jing-Wang
    Li, Zhan-Liang
    Yao, Yong-Ming
    Jiao, Hua-Bo
    Yin, Hui-Nan
    Zhu, Zi-Man
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2014, 8 (01) : 141 - 146
  • [30] Use of a low molecular weight heparin (enoxaparin) as an anticoagulant for cardiopulmonary bypass (CPB).
    Lutz, P
    Moody, C
    Levitsky, S
    BLOOD, 1996, 88 (10) : 3064 - 3064
12345